Abschluss eines nicht exklusiven Rabattvertrages nach§ 130a Abs. 8 SGB V zu Arzneimitteln mit der Wirkstoffkombination aus Drospirenon und Ethinylestradiol (ATC-Code: G03AA12) innerhalb des Zeitraumes vom 01.11.2026 bis zum 31.10.2028 mit jederzeitiger Möglichkeit des Vertragsabschlusses während der Laufzeit („open-house-Modell“).

TENDER DESCRIPTION

For the active ingredient combination of drospirenone and ethinylestradiol (ATC code: G03AA12), AOK Niedersachsen offers discount contracts. For the period until the coming into force of exclusive contracts as a result of a formal procurement procedure in accordance with the provisions of Part 4 of the GWB, AOK Niedersachsen offers interested pharmaceutical companies, without an selection decision, discount contracts to all interested pharmaceutical companies. Contract awards are made within the framework of an “open-house model” and serve as a bridge between the start of generic competition (expiry of patents) and the award of exclusive contracts. The contracts offered are non-exclusive; AOK Niedersachsen requests contracts with all market participants (pharmaceutical companies). In the open-house model, uniform terms apply to all participants. Contract contents, conditions and access procedures are uniform—individual negotiations are generally not conducted. Contract terms are a maximum of twenty-four months; the earliest contract start date is 01.11.2026. All contracts end at the latest on 31.10.2028, regardless of the date on which the respective contract is concluded.…

TENDER BRIEF

TENDER DOCUMENTS